Compare Adaptive Biotechnologies Corp (ADPT) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Wix.Com Ltd — how do they compare? Adaptive Biotechnologies Corp trades at $24.96 (market cap $4.04B), while Wix.Com Ltd trades at $66.71 (market cap $2.79B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| ADPT | WIX | |
|---|---|---|
Market Cap | $4.04B | $2.79B |
Sector | Health | Technology |
52-Week High | $25.45 | $184.24 |
52-Week Low | $12.30 | $40.43 |
Enterprise Value | $4.10B | $3.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
WIX trades at $66.60, up 6.69% today, with a bullish technical signal from moving averages and a consensus analyst price target of $79.75. Revenue grew to $1.99B in 2025, though net income margin remains negative at -8.19%. Recent news includes the launch of Symphony by Wix, an AI system for SMBs, but the stock faces multiple class-action lawsuits following a 27% drop after Q1 2026 earnings missed expectations.
The outlook is mixed: strong revenue growth and analyst buy ratings suggest upside, but legal risks and volatile earnings pose significant challenges. Investors should weigh the high P/E of 62.84 against competitive pressures in the website-building space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
